FDA Grants Priority Review for NUPLAZID Supplement NDA210793
The FDA has granted priority review status for the supplemental NDA for NUPLAZID, an indication for pimavanserin tartrate.
Asset / Drug
Drug and asset intelligence for NUPLAZID with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has accepted a supplemental NDA for NUPLAZID (pimavanserin tartrate) from ACADIA Pharmaceuticals.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.